Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.50 |
| ▸ | FEN1 | P39748 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | RXRA | P19793 | 4/20 | 0.49 |
| ▸ | RXRB | P28702 | 4/20 | 0.49 |
| ▸ | RXRG | P48443 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | DBH | P09172 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.48 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.48 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.48 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9039300 | 0.85 | KMO (0.56) | KMOHDAC8GAAERCC5FEN1 | |
| SCHEMBL7945435 | 0.83 | GAA (0.59) | HDAC8GAATDP1KDM4EDBH | |
| SCHEMBL14564385 | 0.82 | KMO (0.62) | KMOHDAC8GAAERCC5FEN1 | |
| SCHEMBL4560389 | 0.82 | KMO (0.53) | KMOHDAC8ERCC5FEN1MAPT | |
| SCHEMBL2625198 | 0.82 | SMN1; SMN2 (0.61) | GAAMAPTTDP1LMNAKDM4E | |
| SCHEMBL1792142 | 0.81 | TDP1 (0.52) | GAAMAPTTDP1LMNAKDM4E | |
| SCHEMBL22013781 | 0.81 | KAT6A (0.49) | GAAKDM4EDBHRECQLGRM5 | |
| SCHEMBL15981520 | 0.81 | MGLL (0.53) | KMOHDAC8GAALMNARXRA | |
| SCHEMBL19863243 | 0.81 | KMO (0.51) | KMOHDAC8GAAERCC5FEN1 | |
| SCHEMBL163939 | 0.81 | TDP1 (0.56) | GAAMAPTTDP1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207355-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG | L-Base Co., Ltd. (KR) | 2024-06-27 | — | — | US | disclosed |
| WO-2024092011-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20230159587-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER | L-Base Co., Ltd. (KR) | 2023-05-25 | — | — | US | disclosed |
| US-20230159587-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER | L-Base Co., Ltd. (KR) | 2023-05-25 | — | — | US | disclosed |
| US-20230121337-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20170144984-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | THE UNITED STATES OF AMERICA AS REPRESENTED BY SECRETARY DEPT OF HEALTH AND HUMAN SERVICE (US) | 2017-05-25 | — | — | US | disclosed |
| US-9452973-B2 | Modulators of the relaxin receptor 1 | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-09-27 | — | — | US | disclosed |
| EP-2479163-B1 | METHOD FOR PRODUCING CYCLOHEXYL ALKYL KETONES | MITSUBISHI GAS CHEMICAL CO (JP) | 2016-06-29 | — | — | EP | disclosed |
| US-20150119426-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES | 2015-04-30 | — | — | US | disclosed |
| US-8507727-B2 | Method for producing cyclohexyl alkyl ketones | MITSUBISHI GAS CHEMCIAL COMPANY, INC. (JP) | 2013-08-13 | — | — | US | disclosed |
| EP-2479163-A1 | METHOD FOR PRODUCING CYCLOHEXYL ALKYL KETONES | Mitsubishi Gas Chemical Company, Inc. (JP) | 2012-07-25 | — | — | EP | disclosed |
| US-20120178970-A1 | METHOD FOR PRODUCING CYCLOHEXYL ALKYL KETONES | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2012-07-12 | — | — | US | disclosed |
| US-7829571-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090124668-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2009-05-14 | — | — | US | disclosed |
| US-7482335-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-27 | — | — | US | disclosed |
| US-7482335-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-27 | — | — | US | disclosed |
| US-20070032526-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CARTER PEROY H | 2007-02-08 | — | — | US | disclosed |
| US-20070032526-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CARTER PEROY H | 2007-02-08 | — | — | US | disclosed |
| US-7163937-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-16 | — | — | US | disclosed |
| US-7163937-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032526-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCL2, CCR1 | KMO 3014/4885HDAC8 2212/4885GAA 4545/4885 |
| US-20230159587-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER | VIP, QPCT, TPT1 | KMO 2095/4885HDAC8 1744/4885GAA 784/4885 |
| US-20150119426-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | RXFP1, RXFP2, RXFP3 | KMO 2597/4885HDAC8 1725/4885GAA 3991/4885 |
| US-20230121337-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK20, CDK2AP2 | KMO 3257/4885HDAC8 389/4885GAA 1581/4885 |
| US-20240207355-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG | ALPG, SLC11A2, SGTA | KMO 1704/4885HDAC8 1114/4885GAA 360/4885 |
| US-20120178970-A1 | METHOD FOR PRODUCING CYCLOHEXYL ALKYL KETONES | HACL2, ALKBH3, HSD17B7 | KMO 68/4885HDAC8 3021/4885GAA 1768/4885 |
| US-20090124668-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCL11, CCL2, CCR1 | KMO 3014/4885HDAC8 2212/4885GAA 4545/4885 |
| US-20170144984-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | RXFP1, RXFP2, RXFP3 | KMO 2597/4885HDAC8 1725/4885GAA 3991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.